1.1M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Jay S. Duker | Director, President and CEO | Other type of transaction at price $ 6.16 per share. | 19 Mar 2025 | 20,000 | 57,651 (0%) | 0% | 6.2 | 123,100 | Common Stock |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 5,834 | 0 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 5,834 | 75,550 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 79,706 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 7,000 | 0 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.49 per share. | 09 Feb 2025 | 2,055 | 77,651 (0%) | 0% | 6.5 | 13,347 | Common Stock |
| Reginald Sanders | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 80,000 | 80,000 | - | - | Stock Options (Right to buy) | |
| Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 25,333 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 75,133 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | Common Stock | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 41,500 | 41,500 | - | - | Stock Option (Right to Buy) | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 14,715 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 63,356 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 5,267 | 58,089 (0%) | 0% | 8.3 | 43,505 | Common Stock |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,285 | 73,374 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 4,808 | 68,566 (0%) | 0% | 8.7 | 41,733 | Common Stock |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 59,000 | 74,000 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 30,000 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 21,400 (0%) | 0% | 0 | Common Stock | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 03 Jan 2025 | 10,007 | 58,020 (0%) | 0% | 8.3 | 82,658 | Common Stock |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 78,814 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 03 Jan 2025 | 6,108 | 72,706 (0%) | 0% | 8.7 | 53,017 | Common Stock |
| Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 195,000 | 228,334 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 60,000 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 20,794 | 39,206 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 30,000 | 68,027 (0%) | 0% | 0 | Common Stock | |
| Stuart M. Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 117,000 | 117,000 | - | - | Stock Option (Right to Buy) | |
| Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 60,000 | 60,000 | - | - | Stock Options (Right to buy) | |
| Goran A. Ando | Director | Purchase of securities on an exchange or from another person at price $ 7.95 per share. | 21 Aug 2024 | 5,000 | 13,150 (0%) | 0% | 8.0 | 39,750 | Common Stock |
| Wendy F. DiCicco | Director | Purchase of securities on an exchange or from another person at price $ 7.79 per share. | 20 Aug 2024 | 2,567 | 9,967 (0%) | 0% | 7.8 | 19,997 | Common Stock |
| Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 7.98 per share. | 19 Aug 2024 | 12,500 | 16,500 (0%) | 0% | 8.0 | 99,750 | Common Stock |
| Nancy S. Lurker | Director | Purchase of securities on an exchange or from another person at price $ 7.88 per share. | 16 Aug 2024 | 3,173 | 97,635 (0%) | 0% | 7.9 | 25,003 | Common Stock |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 1,558 | 0 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 16,666 | 16,666 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 16,666 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 56,350 | 169,050 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 56,350 | 281,750 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 30,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 30,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 26,713 | 182,535 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 26,713 | 31,165 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 1,558 | 74,800 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Jul 2024 | 11,625 | 1,850 (0%) | 0% | 10.1 | 116,995 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 12 Jul 2024 | 3,250 | 6,950 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 12 Jul 2024 | 6,525 | 13,475 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 3,250 | 3,250 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 6,525 | 6,525 | - | - | Stock Option (Right to Buy) | |
| Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 94,462 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 22,223 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 16,666 | 46,086 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.69 per share. | 10 Jul 2024 | 8,059 | 38,027 (0%) | 0% | 8.7 | 70,033 | Common Stock |
| Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 16,666 | 33,334 | - | - | Restricted Stock Units | |
| Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 03 Jun 2024 | 6,525 | 12,075 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 6,525 | 13,050 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,250 | 6,500 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 10.30 per share. | 03 Jun 2024 | 11,625 | 3,700 (0%) | 0% | 10.3 | 119,705 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 03 Jun 2024 | 3,250 | 15,325 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 7,500 | 15,000 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.16 per share. | 25 May 2024 | 3,627 | 47,480 (0%) | 0% | 11.2 | 40,477 | Common Stock |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 7,500 | 51,107 (0%) | 0% | 0 | Common Stock | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 3,250 | 9,750 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 6,525 | 19,575 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 14 May 2024 | 6,525 | 13,925 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 14 May 2024 | 3,250 | 17,175 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 12.65 per share. | 14 May 2024 | 11,625 | 5,550 (0%) | 0% | 12.6 | 147,045 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 5,834 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 2,957 | 74,176 (0%) | 0% | 20.7 | 61,121 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 15,493 | 77,133 (0%) | 0% | 20.7 | 320,240 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 14,000 | 92,626 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 30,570 | 78,626 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.67 per share. | 30 Mar 2024 | 7,096 | 67,080 (0%) | 0% | 20.7 | 146,674 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 5,834 | 48,056 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 14,000 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 30,570 | 0 | - | - | Restricted Stock Units | |
| Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 29,420 (0%) | 0% | 0 | Common Stock | |
| Jay Duker S. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Feb 2024 | 2,500 | 22,500 (0%) | 0% | 0 | Common Stock | |
| Duker S. Jay | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Jay Duker S. | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2024 | 20,000 | 31,920 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 40,966 (0%) | 0% | 0 | Common Stock | |
| Lurker Nancy S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 5,834 | - | - | Restricted Stock Units | |
| Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 4,452 | 155,822 | - | - | Stock Option (Right to Buy) | |
| S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 3,116 | 1,558 | - | - | Stock Option (Right to Buy) | |
| Paggiarino A. Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 5,834 | - | - | Restricted Stock Units | |
| Duker S. Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 7,000 | 50,486 (0%) | 0% | 0 | Common Stock | |
| Duker Jay S. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,075 | 53,378 (0%) | 0% | 28.8 | 59,760 | Common Stock |
| George Elston O. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,458 | 43,607 (0%) | 0% | 28.8 | 41,990 | Common Stock |
| Paggiarino A. Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 41,472 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,458 | 51,920 (0%) | 0% | 28.8 | 41,990 | Common Stock |
| Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 126,889 (0%) | 0% | 0 | Common Stock | |
| Lurker S. Nancy | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 7,962 | 165,013 (0%) | 0% | 28.8 | 229,306 | Common Stock |
| Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 83,351 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 48,572 (0%) | 0% | 0 | Common Stock | |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 43,572 (0%) | 0% | 0 | Common Stock | |
| Jay Duker S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 7,000 | 7,000 | - | - | Restricted Stock Units | |
| George Elston O. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,734 | 45,065 (0%) | 0% | 28.8 | 49,939 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,701 | 44,916 (0%) | 0% | 28.8 | 48,989 | Common Stock |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 47,305 (0%) | 0% | 0 | Common Stock | |
| Paggiarino Dario A. | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,565 | 42,222 (0%) | 0% | 28.8 | 73,872 | Common Stock |
| Nancy Lurker S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 4,452 | 57,878 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,955 | 46,617 (0%) | 0% | 28.8 | 56,304 | Common Stock |
| Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 3,116 | 73,242 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 6,981 | 158,032 (0%) | 0% | 28.8 | 201,053 | Common Stock |
| Duker S. Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| S. Jay Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 55,453 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Paggiarino Dario A. | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 2,518 | 44,787 (0%) | 0% | 28.8 | 72,518 | Common Stock |
| Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 0 | - | - | Restricted Stock Units | |
| S. Nancy Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 155,441 (0%) | 0% | 0 | Common Stock | |
| Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Elston George O. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,833 | 46,799 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 172,975 (0%) | 0% | 0 | Common Stock | |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 02 Feb 2024 | 209 | 38,171 (0%) | 0% | 11.5 | 2,397 | Common Stock |
| Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 02 Feb 2024 | 209 | 37,962 (0%) | 0% | 28.5 | 5,954 | Common Stock |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 209 | 4,375 | - | - | Stock Option (Right to Buy) | |
| Jones David Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 26 Jan 2024 | 16,413 | 47,566 (0%) | 0% | 25.4 | 417,653 | Common Stock |
| Paggiarino A. Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 26 Jan 2024 | 15,609 | 70,170 (0%) | 0% | 25.4 | 396,572 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 33,665 | 17,588 | - | - | Stock Option (Right to Buy) | |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 15,609 | 52,114 (0%) | 0% | 12.9 | 201,356 | Common Stock |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Jan 2024 | 16,413 | 63,979 (0%) | 0% | 3.3 | 53,506 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 26 Jan 2024 | 33,665 | 85,830 (0%) | 0% | 13.1 | 442,021 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.14 per share. | 26 Jan 2024 | 51 | 52,165 (0%) | 0% | 13.1 | 670 | Common Stock |
| Paggiarino A. Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 51 | 51,253 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.77 per share. | 26 Jan 2024 | 33,665 | 36,505 (0%) | 0% | 25.8 | 867,672 | Common Stock |
| Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 9,604 | 47,566 (0%) | 0% | 12.9 | 123,892 | Common Stock |
| A. Dario Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 26 Jan 2024 | 51 | 85,779 (0%) | 0% | 25.4 | 1,296 | Common Stock |
| Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 26 Jan 2024 | 9,604 | 37,962 (0%) | 0% | 25.3 | 242,717 | Common Stock |
| Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 16,413 | 68,742 | - | - | Stock Option (Right to Buy) | |
| David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,604 | 8,721 | - | - | Stock Option (Right to Buy) | |
| Paggiarino Dario A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 15,609 | 1,026 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 300 | 16,635 | - | - | Stock Option (Right to Buy) | |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 300 | 51,304 | - | - | Stock Option (Right to Buy) | |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 25 Jan 2024 | 300 | 36,805 (0%) | 0% | 13.1 | 3,939 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 25 Jan 2024 | 300 | 36,505 (0%) | 0% | 25 | 7,500 | Common Stock |
| Dario Paggiarino A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 25 Jan 2024 | 300 | 37,105 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 25 Jan 2024 | 300 | 36,805 (0%) | 0% | 25 | 7,500 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,600 | 18,625 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,600 | 37,962 (0%) | 0% | 25.0 | 140,068 | Common Stock |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 85,155 | - | - | Stock Option (Right to Buy) | |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 5,700 | 49,262 (0%) | 0% | 3.3 | 18,582 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,700 | 43,562 (0%) | 0% | 25.0 | 142,554 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,700 | 85,455 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 25 | 7,500 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 18,325 | - | - | Stock Option (Right to Buy) | |
| David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 37,962 (0%) | 0% | 25 | 7,500 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 5,600 | 43,562 (0%) | 0% | 12.9 | 72,240 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 300 | 38,562 (0%) | 0% | 3.3 | 978 | Common Stock |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 3,096 | 57,204 | - | - | Stock Option (Right to Buy) | |
| Paggiarino A. Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 23 Jan 2024 | 5,651 | 42,156 (0%) | 0% | 12.9 | 72,898 | Common Stock |
| S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jan 2024 | 112,700 | 112,700 | - | - | Stock Option (Right to Buy) | |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 23 Jan 2024 | 3,096 | 39,601 (0%) | 0% | 13.1 | 40,650 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 23 Jan 2024 | 3,096 | 36,505 (0%) | 0% | 25 | 77,400 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 23 Jan 2024 | 5,600 | 42,156 (0%) | 0% | 25.0 | 140,052 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.13 per share. | 23 Jan 2024 | 5,600 | 47,756 (0%) | 0% | 13.1 | 73,528 | Common Stock |
| Paggiarino Dario A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 5,600 | 51,604 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 5,651 | 16,935 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 2,039 | 22,586 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 23 Jan 2024 | 5,651 | 36,505 (0%) | 0% | 25.0 | 141,363 | Common Stock |
| Paggiarino A. Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 23 Jan 2024 | 2,039 | 39,601 (0%) | 0% | 25 | 50,975 | Common Stock |
| S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jan 2024 | 112,700 | 338,100 | - | - | Stock Option (Right to Buy) | |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 23 Jan 2024 | 2,039 | 41,640 (0%) | 0% | 12.9 | 26,303 | Common Stock |
| Nancy S. Lurker | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 23 Jan 2024 | 29,956 | 135,441 (0%) | 0% | 25.0 | 748,250 | Common Stock |
| S. Lurker Nancy | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.97 per share. | 23 Jan 2024 | 5,044 | 165,397 (0%) | 0% | 25.0 | 125,950 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 500 | 37,962 (0%) | 0% | 25 | 12,500 | Common Stock |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 22 Jan 2024 | 400 | 38,362 (0%) | 0% | 12.9 | 5,160 | Common Stock |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 400 | 24,225 | - | - | Stock Option (Right to Buy) | |
| Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 22 Jan 2024 | 28,750 | 37,962 (0%) | 0% | 22.7 | 652,254 | Common Stock |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 22 Jan 2024 | 500 | 38,862 (0%) | 0% | 3.3 | 1,630 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 500 | 91,155 | - | - | Stock Option (Right to Buy) | |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 28,750 | 31,250 | - | - | Stock Option (Right to Buy) | |
| Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 22 Jan 2024 | 5,416 | 72,128 (0%) | 0% | 11.5 | 62,122 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 5,416 | 4,584 | - | - | Stock Option (Right to Buy) | |
| Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.24 per share. | 22 Jan 2024 | 5,416 | 66,712 (0%) | 0% | 22.2 | 120,437 | Common Stock |
| David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 400 | 38,462 (0%) | 0% | 25 | 10,000 | Common Stock |
| Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 22 Jan 2024 | 28,750 | 66,712 (0%) | 0% | 10.1 | 291,238 | Common Stock |
| Ye Liu | Director | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 11 Jan 2024 | 1,910,500 | 100,221 (0%) | 1% | 19.5 | 37,159,225 | Common Stock, $0.001 par value |
| Paggiarino Dario A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 08 Jan 2024 | 22,913 | 59,418 (0%) | 0% | 3.3 | 74,696 | Common Stock |
| Paggiarino A. Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2024 | 22,913 | 68,742 | - | - | Stock Option (Right to Buy) | |
| A. Dario Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.13 per share. | 08 Jan 2024 | 22,913 | 36,505 (0%) | 0% | 21.1 | 484,124 | Common Stock |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| Lurker Nancy S. | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 38,000 | 38,000 | - | - | Restricted Stock Units | |
| S. Duker Jay | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 6,528 | 43,486 (0%) | 0% | 20.4 | 133,171 | Common Stock |
| Lurker Nancy S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 75,133 | 150,267 | - | - | Restricted Stock Units | |
| A. Goran Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 23,598 | 23,598 | - | - | Stock Option (Right to Buy) | |
| O. George Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| S. Duker Jay | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 20,793 | 41,587 | - | - | Restricted Stock Units | |
| David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,147 | 37,962 (0%) | 0% | 20.4 | 84,599 | Common Stock |
| Pine C. Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| Duker Jay S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 20,793 | 50,014 (0%) | 0% | 0 | Common Stock | |
| P. Adamis Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| Duker S. Jay | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| George Elston O. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| Landis John B. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Stuart Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| Elston George O. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| Nancy Lurker S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 75,133 | 193,484 (0%) | 0% | 0 | Common Stock | |
| Paggiarino A. Dario | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,487 | 36,505 (0%) | 0% | 20.4 | 91,535 | Common Stock |
| Pine C. Michael | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| S. Nancy Lurker | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 77,000 | 77,000 | - | - | Stock Option (Right to Buy) | |
| S. Nancy Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 23,043 | 170,441 (0%) | 0% | 20.4 | 470,077 | Common Stock |
| Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| C. Michael Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 19,628 (0%) | 0% | 0 | Common Stock | |
| S. Duker Jay | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Restricted Stock Units | |
| A. Dario Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| C. Michael Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Pine C. Michael | Chief Corp Dev.&Strat. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 5,966 | 13,662 (0%) | 0% | 20.4 | 121,706 | Common Stock |
| A. Dario Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 40,992 (0%) | 0% | 0 | Common Stock | |
| George Elston O. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,911 | 35,308 (0%) | 0% | 20.4 | 100,184 | Common Stock |
| Landis B. John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 42,109 (0%) | 0% | 0 | Common Stock | |
| R. David Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 40,219 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 35,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Lurker Nancy S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 52,208 | 52,208 (0%) | 0% | 0 | Common Stock | |
| Lurker Nancy S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 31,164 | 151,370 | - | - | Stock Option (Right to Buy) | |
| S. Nancy Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 31,164 | 62,330 | - | - | Stock Option (Right to Buy) | |
| S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 10,906 | 70,126 | - | - | Stock Option (Right to Buy) | |
| S. Nancy Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 52,208 | 118,351 (0%) | 0% | 0 | Common Stock | |
| Lurker Nancy S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 10,906 | 4,674 | - | - | Stock Option (Right to Buy) | |
| Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2023 | 35,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Dario Paggiarino A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2023 | 1,458 | 37,917 | - | - | Stock Option (Right to Buy) | |
| Paggiarino Dario A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 13 Dec 2023 | 1,458 | 27,165 (0%) | 0% | 10.1 | 14,770 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 13 Dec 2023 | 1,458 | 25,707 (0%) | 0% | 20 | 29,160 | Common Stock |
| Liu Ye | Director | Sale of securities on an exchange or to another person at price $ 18.41 per share. | 05 Dec 2023 | 266,242 | 2,010,721 (1%) | 0% | 18.4 | 4,901,515 | Common Stock, $0.001 par value |
| Liu Ye | Director | Sale of securities on an exchange or to another person at price $ 19.91 per share. | 05 Dec 2023 | 733,758 | 2,276,963 (1%) | 0% | 19.9 | 14,609,122 | Common Stock, $0.001 par value |
| Pine Michael C. | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 45,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Lurker S. Nancy | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 04 Dec 2023 | 20,000 | 170,559 (0%) | 0% | 20.8 | 415,200 | Common Stock |
| A. Dario Paggiarino | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 30,625 | 25,707 (0%) | 0% | 22 | 673,750 | Common Stock |
| Dario Paggiarino A. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 30,625 | 39,375 | - | - | Stock Option (Right to Buy) | |
| C. Pine Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | Common Stock |
| C. Michael Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 20.79 per share. | 04 Dec 2023 | 1,000 | 4,343 (0%) | 0% | 20.8 | 20,790 | Common Stock |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | Common Stock |
| A. Paggiarino Dario | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 04 Dec 2023 | 30,625 | 56,332 (0%) | 0% | 10.1 | 310,231 | Common Stock |
| Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 66,666 | 66,666 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 33,334 | 33,334 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Anthony P. Adamis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 225,400 | 225,400 | - | - | Restricted Stock Units | |
| Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 27,100 | 27,100 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,500 | 13,500 | - | - | Stock Option (Right to Buy) | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| Jay S. Duker | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 62,380 | 62,380 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| Ye Liu | Director | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 30 May 2023 | 1 | 3,010,721 (2%) | 0% | 6 | 6 | Common Stock, $0.001 par value |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 22,500 | 22,500 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 75,000 | 165,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 21,250 | 0 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 21,250 | 85,000 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 65,868 | 0 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 65,868 | 93,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 36,000 | 0 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 36,000 | 54,000 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 8,000 | 0 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 8,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 120,206 | 93,494 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 120,206 | 120,206 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 59,220 | 15,580 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 59,220 | 59,220 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 7,400 (0%) | 0% | 0 | Common Stock | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 17,533 | 17,534 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 17,533 | 170,559 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 20,000 | 190,559 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 20,000 | 40,000 | - | - | Restricted Stock Units | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,250 | 8,150 (0%) | 0% | 0 | Common Stock | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,250 | 0 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 7,400 (0%) | 0% | 0 | Common Stock | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 0 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,833 | 11,667 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,116 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,833 | 18,149 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 11,400 (0%) | 0% | 0 | Common Stock | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,722 | 25,707 (0%) | 0% | 4.2 | 7,181 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,833 | 11,667 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,618 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 2,022 | 27,429 (0%) | 0% | 4.2 | 8,432 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,833 | 29,451 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 2,426 | 30,943 (0%) | 0% | 4.2 | 10,116 | Common Stock |
| Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 33,369 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 7,000 | 28,402 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 7,000 | 14,000 | - | - | Restricted Stock Units | |
| Jay S. Duker | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| Jay S. Duker | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,722 | 29,221 (0%) | 0% | 4.2 | 7,181 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,089 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 28,089 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,483 | 26,606 (0%) | 0% | 4.2 | 6,184 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,473 | 25,133 (0%) | 0% | 4.2 | 6,142 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 450,800 | 450,800 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 124,755 | 124,755 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 15,258 | 0 | - | - | Restricted Stock Units | |
| Jay S. Duker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 15,258 | 25,881 (0%) | 0% | 0 | Common Stock | |
| Jay S. Duker | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 01 Nov 2022 | 4,479 | 21,402 (0%) | 0% | 5.4 | 24,276 | Common Stock |
| Jay S. Duker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2022 | 65,300 | 65,300 | - | - | Stock Option (Right to Buy) | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Anthony P. Adamis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Purchase of securities on an exchange or from another person at price $ 12.21 per share. | 14 Mar 2022 | 1,000 | 1,000 (0%) | 0% | 12.2 | 12,210 | Common Stock |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 12,466 | 0 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 12,466 | 150,281 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 19,945 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 28 Feb 2022 | 1,294 | 18,651 (0%) | 0% | 9.9 | 12,875 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 0 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 28 Feb 2022 | 1,130 | 15,599 (0%) | 0% | 10.0 | 11,244 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 16,729 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 0 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 13,717 | 137,815 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 13,717 | 13,718 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 11,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 4,400 (0%) | 0% | 0 | Common Stock | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 0 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,250 | 3,250 | - | - | Restricted Stock Units | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,750 | 4,900 (0%) | 0% | 0 | Common Stock | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,750 | 0 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 4,400 (0%) | 0% | 0 | Common Stock | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 0 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 11,323 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,721 | 9,602 (0%) | 0% | 10.1 | 17,434 | Common Stock |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 8,400 (0%) | 0% | 0 | Common Stock | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 0 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,721 | 15,840 (0%) | 0% | 10.1 | 17,434 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 17,561 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,473 | 12,624 (0%) | 0% | 10.1 | 14,921 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 14,097 (0%) | 0% | 0 | Common Stock | |
| Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.15 per share. | 15 Nov 2021 | 10,000 | 103,546 (0%) | 0% | 20.1 | 201,480 | Common Stock |
| Jay S. Duker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 239,700 | 239,700 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 213,700 | 213,700 | - | - | Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 52,600 | 52,600 | - | - | Restricted Stock Units | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,750 | 2,750 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Douglas E. Godshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 0 | - | - | Restricted Stock Units | |
| Douglas E. Godshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Douglas E. Godshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 8,016 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 14,900 | 14,900 | - | - | Restricted Stock Units | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 60,300 | 60,300 | - | - | Stock Option (Right to Buy) | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 60,300 | 60,300 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 14,900 | 14,900 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 60,300 | 60,300 | - | - | Stock Option (Right to Buy) | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 14,900 | 19,005 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 1,900 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 12,467 | 109,046 (0%) | 0% | 0 | Common Stock | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 12,467 | 12,466 | - | - | Restricted Stock Units | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,150 | 2,150 (0%) | 0% | 0 | Common Stock | |
| Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,150 | 0 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 1,900 (0%) | 0% | 0 | Common Stock | |
| Douglas E. Godshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units | |
| Douglas E. Godshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 5,516 (0%) | 0% | 0 | Common Stock | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 5,900 (0%) | 0% | 0 | Common Stock | |
| John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.81 per share. | 28 Feb 2021 | 1,423 | 11,592 (0%) | 0% | 10.8 | 15,383 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 13,015 (0%) | 0% | 0 | Common Stock | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 4,105 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 9,082 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 4,105 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.81 per share. | 28 Feb 2021 | 1,702 | 7,380 (0%) | 0% | 10.8 | 18,399 | Common Stock |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 13,717 | 13,718 | - | - | Restricted Stock Units | |
| Nancy S. Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 13,717 | 96,579 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.48 per share. | 04 Sep 2020 | 10,000 | 40,000 (0%) | 0% | 0.5 | 4,800 | Common Stock |
| George O. Elston | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 24 Aug 2020 | 10,000 | 30,000 (0%) | 0% | 0.6 | 6,112 | Common Stock |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 124,667 | 784,467 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 124,667 | 249,333 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 30 Jun 2020 | 12,049 | 89,144 (0%) | 0% | 0.8 | 9,121 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 82,100 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 101,193 (0%) | 0% | 0 | Common Stock | |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 82,100 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 30 Jun 2020 | 14,060 | 26,990 (0%) | 0% | 0.8 | 10,643 | Common Stock |
| David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 41,050 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2020 | 40,000 | 659,800 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2020 | 40,000 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.79 per share. | 27 Jun 2020 | 2,936 | 60,143 (0%) | 0% | 0.8 | 2,317 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2020 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2020 | 10,000 | 63,079 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2020 | 45,000 | 619,800 (0%) | 0% | 0 | Common Stock | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2020 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2020 | 14,200 | 14,200 | - | - | Restricted Stock Units | |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 14 Jun 2020 | 4,168 | 53,079 (0%) | 0% | 0.8 | 3,441 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2020 | 14,200 | 57,247 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.96 per share. | 12 Mar 2020 | 10,000 | 20,000 (0%) | 0% | 1.0 | 9,600 | Common Stock |
| Nancy Lurker | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.06 per share. | 10 Mar 2020 | 98,000 | 574,800 (0%) | 0% | 1.1 | 104,027 | Common Stock |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| David J. Mazzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| David J. Mazzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| Nancy Lurker | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 374,000 | 374,000 | - | - | Restricted Stock Units | |
| Nancy Lurker | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 748,000 | 748,000 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 38,500 | 38,500 | - | - | Stock Option (Right to Buy) | |
| Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 21,500 | 21,500 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| Wendy F. DiCicco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| Douglas E. Godshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| Douglas E. Godshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 110,371 | 110,371 | - | - | Stock Option (Right to Buy) | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 246,250 | 246,250 | - | - | Stock Option (Right to Buy) | |
| Dario A. Paggiarino | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 123,150 | 123,150 | - | - | Restricted Stock Units | |
| Jay S. Duker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 33,500 | 33,500 | - | - | Stock Option (Right to Buy) | |
| Jay S. Duker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 19,000 | 19,000 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 123,150 | 123,150 | - | - | Restricted Stock Units | |
| David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 246,250 | 246,250 | - | - | Stock Option (Right to Buy) | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2020 | 137,174 | 274,349 | - | - | Restricted Stock Units | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2020 | 137,174 | 476,800 (0%) | 0% | 0 | Common Stock | |
| George O. Elston | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 Nov 2019 | 10,000 | 10,000 (0%) | 0% | 1.4 | 14,290 | Common Stock |
| George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2019 | 745,000 | 745,000 | - | - | Stock Options (Right to buy) | |
| Nancy Lurker | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.10 per share. | 12 Oct 2019 | 10,745 | 314,455 (0%) | 0% | 2.1 | 22,618 | Common Stock |
| Dario A. Paggiarino | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.10 per share. | 12 Oct 2019 | 2,450 | 43,047 (0%) | 0% | 2.1 | 5,157 | Common Stock |
| David J. Mazzo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.95 per share. | 09 Oct 2019 | 33,333 | 200,083 (0%) | 0% | 1.9 | 64,999 | Common Stock |
| David J. Mazzo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2019 | 33,333 | 0 | - | - | Stock Option (Right to Buy) | |
| David J. Mazzo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2019 | 417 | 166,750 (0%) | 0% | 0 | Common Stock | |
| David J. Mazzo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2019 | 417 | 0 | - | - | Deferred Stock Unit | |
| Wendy F. DiCicco | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2019 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2019 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Nancy Lurker | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2019 | 40,000 | 325,200 (0%) | 0% | 0 | Common Stock | |
| Leonard S. Ross | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2019 | 6,667 | 92,005 (0%) | 0% | 0 | Common Stock | |
| Leonard S. Ross | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2019 | 6,667 | 6,667 | - | - | Restricted Stock Units |